FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1594-1602 November 30, 2000 Number 22 Next

	Full Text PDF Editorial by Klippel, J. H. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Neutralization of tumor necrosis factor (TNF-) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known.

Methods We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-, in intravenous doses of 3 or 10 mg per kilogram of body weight every 4 or 8 weeks in combination with oral methotrexate for 54 weeks. We assessed clinical responses with use of the criteria of the American College of Rheumatology, the quality of life with a health-status questionnaire, and the effect on joint damage radiographically.

Results The combination of infliximab and methotrexate was well tolerated and resulted in a sustained reduction in the symptoms and signs of rheumatoid arthritis that was significantly greater than the reduction associated with methotrexate therapy alone (clinical response, 51.8 percent vs. 17.0 percent; P<0.001). The quality of life was also significantly better with infliximab plus methotrexate than with methotrexate alone. Radiographic evidence of joint damage increased in the group given methotrexate, but not in the groups given infliximab and methotrexate (mean change in radiographic score, 7.0 vs. 0.6; P<0.001). Radiographic evidence of progression of joint damage was absent in infliximab-treated patients whether or not they had a clinical response.

Conclusions In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotrexate provided clinical benefit and halted the progression of joint damage.

Source Information

From the University of Texas Southwestern Medical Center at Dallas, Dallas (P.E.L.); University Hospital Maastricht, Maastricht, the Netherlands (D.M.F.M.H.); Duke University Medical Center, Durham, N.C. (E.W.S.), Virginia Mason Research Center, Seattle (D.E.F.); the University of Leiden, Leiden, the Netherlands (F.C.B.); the Institute for Clinical Immunology, Erlangen, Germany (J.R.K.); the University of Vienna, Vienna, Austria (J.S.S.); the University of California at San Diego, San Diego (M.W.); the Research School of Medicine, University of Leeds, Leeds, United Kingdom (P.E.); the Kennedy Institute of Rheumatology and the Imperial College School of Medicine at Charing Cross Hospital, London (M.F., R.N.M.); and Centocor, Malvern, Pa. (G.R.H.).

Address reprint requests to Dr. Lipsky at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Bldg. 10, Rm. 9N228, Bethesda, MD 20892-1820, or at lipskyp{at}mail.nih.gov.

Full Text of this Article

This article has been cited by other articles:

• Finckh, A, Ciurea, A, Brulhart, L, Moller, B, Walker, U A, Courvoisier, D, Kyburz, D, Dudler, J, Gabay, C, on the behalf of the doctors of the Swiss Clinical, (2010). Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. Ann Rheum Dis 69: 387-393 [Abstract] [Full Text]  
• Izhak, L., Wildbaum, G., Uri, W., Shaked, Y., Alami, J., Dumont, D., Stein, A., Karin, N. (2010). Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner. J. Immunol. 184: 1092-1101 [Abstract] [Full Text]  
• Grijalva, C. G., Kaltenbach, L., Arbogast, P. G., Mitchel, E. F. Jr, Griffin, M. R. (2010). Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 49: 82-90 [Abstract] [Full Text]  
• Martin, J, Walsh, C, Gibbs, A, McDonnell, T, Fearon, U, Keane, J, Codd, M B, Dodd, J, Veale, D, FitzGerald, O, Bresnihan, B (2010). Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 69: 181-185 [Abstract] [Full Text]  
• Augustsson, J, Neovius, M, Cullinane-Carli, C, Eksborg, S, van Vollenhoven, R F (2010). Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis 69: 126-131 [Abstract] [Full Text]  
• Furst, D E, Keystone, E C, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Braun, J, Bresnihan, B, Burmester, G R, De Benedetti, F, Dorner, T, Emery, P, Gibofsky, A, Kavanaugh, A, Kirkham, B, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H, Winthrop, K (2010). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 69: i2-i29 [Full Text]  
• Feldmann, M, Williams, R O, Paleolog, E (2010). What have we learnt from targeted anti-TNF therapy?. Ann Rheum Dis 69: i97-i99 [Abstract] [Full Text]  
• Burgos, P. I., Danila, M. I., Kelley, J. M., Hughes, L. B., Bridges, S. L. Jr (2009). Understanding personalized medicine in rheumatoid arthritis: a clinician's guide to the future. Therapeutic Advances in Musculoskeletal Diseases 1: 97-105 [Abstract]  
• Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., Ghogomu, E. T., Tugwell, P. (2009). A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 181: 787-796 [Abstract] [Full Text]  
• Radstake, T R D J, Svenson, M, Eijsbouts, A M, van den Hoogen, F H J, Enevold, C, van Riel, P L C M, Bendtzen, K (2009). Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68: 1739-1745 [Abstract] [Full Text]  
• Canete, J D, Suarez, B, Hernandez, M V, Sanmarti, R, Rego, I, Celis, R, Moll, C, Pinto, J A, Blanco, F J, Lozano, F (2009). Influence of variants of Fc{gamma} receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor {alpha} therapy in rheumatoid arthritis. Ann Rheum Dis 68: 1547-1552 [Abstract] [Full Text]  
• Smolen, J S, van der Heijde, D M, Aletaha, D, Xu, S, Han, J, Baker, D, Clair, E W S. (2009). Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis 68: 1535-1540 [Abstract] [Full Text]  
• Haavardsholm, E A, Ostergaard, M, Hammer, H B, Boyesen, P, Boonen, A, van der Heijde, D, Kvien, T K (2009). Monitoring anti-TNF{alpha} treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. Ann Rheum Dis 68: 1572-1579 [Abstract] [Full Text]  
• Dohn, U M., Boonen, A, Hetland, M L, Hansen, M S, Knudsen, L S, Hansen, A, Madsen, O R, Hasselquist, M, Moller, J M, Ostergaard, M (2009). Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 68: 1585-1590 [Abstract] [Full Text]  
• Sany, J., Cohen, J.-D., Combescure, C., Bozonnat, M.-C., Roch-Bras, F., Lafon, G., Daures, J.-P. (2009). Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years. Rheumatology (Oxford) 48: 1236-1241 [Abstract] [Full Text]  
• Hyrich, K. L., Deighton, C., Watson, K. D., BSRBR Control Centre Consortium, , Symmons, D. P. M., Lunt, M., on behalf of the British Society for Rheumatology, (2009). Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford) 48: 1323-1327 [Abstract] [Full Text]  
• Hakim, A. W., Dong, X.-D., Svensson, P., Kumar, U., Cairns, B. E. (2009). TNF{alpha} Mechanically Sensitizes Masseter Muscle Afferent Fibers of Male Rats. J. Neurophysiol. 102: 1551-1559 [Abstract] [Full Text]  
• Bansard, C., Lequerre, T., Daveau, M., Boyer, O., Tron, F., Salier, J.-P., Vittecoq, O., Le-Loet, X. (2009). Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?. Rheumatology (Oxford) 48: 1021-1028 [Abstract] [Full Text]  
• Elewaut, D., Matucci-Cerinic, M. (2009). Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 48: 1029-1035 [Abstract] [Full Text]  
• Vastesaeger, N., Xu, S., Aletaha, D., St Clair, E. W., Smolen, J. S. (2009). A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 48: 1114-1121 [Abstract] [Full Text]  
• Kerbleski, J. F, Gottlieb, A. B (2009). Dermatological complications and safety of anti-TNF treatments. Gut 58: 1033-1039 [Full Text]  
• LEE, S. J., CHANG, H., YAZICI, Y., GREENBERG, J. D., KREMER, J. M., KAVANAUGH, A. (2009). Utilization Trends of Tumor Necrosis Factor Inhibitors Among Patients with Rheumatoid Arthritis in a United States Observational Cohort Study. The Journal of Rheumatology 36: 1611-1617 [Abstract] [Full Text]  
• van Vollenhoven, R. F (2009). How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Ann Rheum Dis 68: 1237-1239 [Full Text]  
• Pavelka, K, Jarosova, K, Suchy, D, Senolt, L, Chroust, K, Dusek, L, Vencovsky, J (2009). Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 68: 1285-1289 [Abstract] [Full Text]  
• Lionaki, S., Siamopoulos, K., Theodorou, I., Papadimitraki, E., Bertsias, G., Boumpas, D., Boletis, J. (2009). Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Nephrol Dial Transplant 24: 2144-2150 [Abstract] [Full Text]  
• Monari, C., Bevilacqua, S., Piccioni, M., Pericolini, E., Perito, S., Calvitti, M., Bistoni, F., Kozel, T. R., Vecchiarelli, A. (2009). A Microbial Polysaccharide Reduces the Severity of Rheumatoid Arthritis by Influencing Th17 Differentiation and Proinflammatory Cytokines Production. J. Immunol. 183: 191-200 [Abstract] [Full Text]  
• EMERY, P., GENOVESE, M. C., van VOLLENHOVEN, R., SHARP, J. T., PATRA, K., SASSO, E. H. (2009). Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. The Journal of Rheumatology 36: 1429-1441 [Abstract] [Full Text]  
• Marotte, H, Gineyts, E, Miossec, P, Delmas, P D (2009). Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis 68: 1197-1200 [Abstract] [Full Text]  
• van der Heijde, D, Burmester, G, Melo-Gomes, J, Codreanu, C, Mola, E M., Pedersen, R, Robertson, D, Chang, D, Koenig, A, Freundlich, B, for the Etanercept Study Investigators, (2009). Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis 68: 1113-1118 [Abstract] [Full Text]  
• Leombruno, J P, Einarson, T R, Keystone, E C (2009). The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68: 1136-1145 [Abstract] [Full Text]  
• Buch, M H, Boyle, D L, Rosengren, S, Saleem, B, Reece, R J, Rhodes, L A, Radjenovic, A, English, A, Tang, H, Vratsanos, G, O'Connor, P, Firestein, G S, Emery, P (2009). Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 68: 1220-1227 [Abstract] [Full Text]  
• van der Kooij, S M, le Cessie, S, Goekoop-Ruiterman, Y P M, de Vries-Bouwstra, J K, van Zeben, D, Kerstens, P J S M, Hazes, J M W, van Schaardenburg, D, Breedveld, F C, Dijkmans, B A C, Allaart, C F (2009). Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 68: 1153-1158 [Abstract] [Full Text]  
• RUSSELL, A. S. (2009). Relative Efficacies: Antimalarials to Abatacept - The Choice Is Ours. The Journal of Rheumatology Supplement 82: 17-24 [Abstract] [Full Text]  
• Smolen, J, Landewe, R B, Mease, P, Brzezicki, J, Mason, D, Luijtens, K, van Vollenhoven, R F, Kavanaugh, A, Schiff, M, Burmester, G R, Strand, V, Vencovsky, J, van der Heijde, D (2009). Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68: 797-804 [Abstract] [Full Text]  
• Keystone, E C, Genovese, M C, Klareskog, L, Hsia, E C, Hall, S T, Miranda, P C, Pazdur, J, Bae, S-C, Palmer, W, Zrubek, J, Wiekowski, M, Visvanathan, S, Wu, Z, Rahman, M U (2009). Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68: 789-796 [Abstract] [Full Text]  
• Motagally, M. A., Lukewich, M. K., Chisholm, S. P., Neshat, S., Lomax, A. E. (2009). Tumour necrosis factor \#945; activates nuclear factor \#954;B signalling to reduce N-type voltage-gated Ca2+ current in postganglionic sympathetic neurons. J. Physiol. 587: 2623-2634 [Abstract] [Full Text]  
• Geens, E., Geusens, P., Vanhoof, J., Berghs, H., Praet, J., Esselens, G., Lens, S., Dufour, J.-P., Vandenberghe, M., Van Mullem, X., Westhovens, R., Verschueren, P. (2009). Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria. Rheumatology (Oxford) 48: 546-550 [Abstract] [Full Text]  
• Kristensen, L. E., Geborek, P., Saxne, T. (2009). Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register. Rheumatology (Oxford) 48: 243-245 [Abstract] [Full Text]  
• Strangfeld, A., Listing, J., Herzer, P., Liebhaber, A., Rockwitz, K., Richter, C., Zink, A. (2009). Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti-TNF-{alpha} Agents. JAMA 301: 737-744 [Abstract] [Full Text]  
• DAVIES, A., CIFALDI, M. A., SEGURADO, O. G., WEISMAN, M. H. (2009). Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis. The Journal of Rheumatology 36: 16-26 [Abstract] [Full Text]  
• Takamatsu, H., Espinoza, J. L., Lu, X., Qi, Z., Okawa, K., Nakao, S. (2009). Anti-Moesin Antibodies in the Serum of Patients with Aplastic Anemia Stimulate Peripheral Blood Mononuclear Cells to Secrete TNF-{alpha} and IFN-{gamma}. J. Immunol. 182: 703-710 [Abstract] [Full Text]  
• Salliot, C, Dougados, M, Gossec, L (2009). Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68: 25-32 [Abstract] [Full Text]  
• van den Bemt, B J F, den Broeder, A A, Snijders, G F, Hekster, Y A, van Riel, P L C M, Benraad, B, Wolbink, G J, van den Hoogen, F H J (2008). Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 67: 1697-1701 [Abstract] [Full Text]  
• Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]  
• Maxwell, J. R., Potter, C., Hyrich, K. L., BRAGGSS, , Barton, A., Worthington, J., Isaacs, J. D., Morgan, A. W., Wilson, A. G. (2008). Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 17: 3532-3538 [Abstract] [Full Text]  
• Isenberg, D, Gordon, C, Merrill, J, Urowitz, M (2008). New therapies in systemic lupus erythematosus - trials, troubles and tribulations.... working towards a solution. Lupus 17: 967-970  
• Smolen, J. S, Weinblatt, M. E (2008). When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?. Ann Rheum Dis 67: 1497-1498 [Full Text]  
• Kapetanovic, M C, Lindqvist, E, Saxne, T, Eberhardt, K (2008). Orthopaedic surgery in patients with rheumatoid arthritis over 20 years: prevalence and predictive factors of large joint replacement. Ann Rheum Dis 67: 1412-1416 [Abstract] [Full Text]  
• Buch, M. H., Reece, R. J., Quinn, M. A., English, A., Cunnane, G., Henshaw, K., Bingham, S. J., Bejarano, V., Isaacs, J., Emery, P. (2008). The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology (Oxford) 47: 1469-1475 [Abstract] [Full Text]  
• Conte, F. d. P., Barja-Fidalgo, C., Verri, W. A. Jr., Cunha, F. Q., Rae, G. A., Penido, C., Henriques, M. d. G. M. O. (2008). Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-{alpha}, and CXCL-1. J. Leukoc. Biol. 84: 652-660 [Abstract] [Full Text]  
• Paltiel, M., Gober, L. M., Deng, A., Mikdashi, J., Alexeeva, I., Saini, S. S., Gaspari, A. A. (2008). Immediate Type I Hypersensitivity Response Implicated in Worsening Injection Site Reactions to Adalimumab. Arch Dermatol 144: 1190-1194 [Abstract] [Full Text]  
• Silva, L., Fernandez-Castro, M., Andreu, J.-L. (2008). Repairing erosions in rheumatoid arthritis. A realistic goal. Rheumatology (Oxford) 47: 1432-1433 [Full Text]  
• van Riel, P L C M, Freundlich, B, MacPeek, D, Pedersen, R, Foehl, J R, Singh, A, on behalf of ADORE study investigators, (2008). Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 67: 1104-1110 [Abstract] [Full Text]  
• La, D T, Collins, C E, Yang, H-T, Migone, T-S, Stohl, W (2008). B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor {alpha} antagonists: differential effects between good and poor clinical responders. Ann Rheum Dis 67: 1132-1138 [Abstract] [Full Text]  
• Gerloni, V, Pontikaki, I, Gattinara, M, Fantini, F (2008). Focus on adverse events of tumour necrosis factor {alpha} blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 67: 1145-1152 [Abstract] [Full Text]  
• Schiff, M, Keiserman, M, Codding, C, Songcharoen, S, Berman, A, Nayiager, S, Saldate, C, Li, T, Aranda, R, Becker, J-C, Lin, C, Cornet, P L N, Dougados, M (2008). Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67: 1096-1103 [Abstract] [Full Text]  
• Hyrich, K. L., Lunt, M., Dixon, W. G., Watson, K. D., Symmons, D. P. M., on behalf of the BSR Biologics Register, (2008). Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 47: 1000-1005 [Abstract] [Full Text]  
• Sekiguchi, N., Kawauchi, S., Furuya, T., Inaba, N., Matsuda, K., Ando, S., Ogasawara, M., Aburatani, H., Kameda, H., Amano, K., Abe, T., Ito, S., Takeuchi, T. (2008). Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-{alpha} monoclonal antibody, infliximab. Rheumatology (Oxford) 47: 780-788 [Abstract] [Full Text]  
• Coates, L. C., Cawkwell, L. S., Ng, N. W. F., Bennett, A. N., Bryer, D. J., Fraser, A. D., Emery, P., Marzo-Ortega, H. (2008). Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 47: 897-900 [Abstract] [Full Text]  
• Coates, L C, Cawkwell, L S, Ng, N W F, Bennett, A N, Bryer, D J, Fraser, A D, Emery, P, Marzo-Ortega, H (2008). Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 67: 717-719 [Abstract] [Full Text]  
• Matsumoto, T., Kaneko, T., Seto, M., Wada, H., Kobayashi, T., Nakatani, K., Tonomura, H., Tono, Y., Ohyabu, M., Nobori, T., Shiku, H., Sudo, A., Uchida, A., Stearns Kurosawa, D. J., Kurosawa, S. (2008). The Membrane Proteinase 3 Expression on Neutrophils Was Downregulated After Treatment With Infliximab in Patients With Rheumatoid Arthritis. CLIN APPL THROMB HEMOST 14: 186-192 [Abstract]  
• Genovese, M C, Schiff, M, Luggen, M, Becker, J-C, Aranda, R, Teng, J, Li, T, Schmidely, N, Le Bars, M, Dougados, M (2008). Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67: 547-554 [Abstract] [Full Text]  
• Emery, P., McInnes, I. B., van Vollenhoven, R., Kraan, M. C. (2008). Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 47: 392-398 [Abstract] [Full Text]  
• Karlsson, J. A., Kristensen, L. E., Kapetanovic, M. C., Gulfe, A., Saxne, T., Geborek, P. (2008). Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47: 507-513 [Abstract] [Full Text]  
• Kristensen, L. E., Kapetanovic, M. C., Gulfe, A., Soderlin, M., Saxne, T., Geborek, P. (2008). Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47: 495-499 [Abstract] [Full Text]  
• Okazaki, K., Kondo, M., Kato, M., Kakinuma, R., Nishida, A., Noda, M., Taniguchi, K., Kimura, H. (2008). Serum Cytokine and Chemokine Profiles in Neonates With Meconium Aspiration Syndrome. Pediatrics 121: e748-e753 [Abstract] [Full Text]  
• Vera-Llonch, M., Massarotti, E., Wolfe, F., Shadick, N., Westhovens, R., Sofrygin, O., Maclean, R., Yuan, Y., Oster, G. (2008). Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford) 47: 535-541 [Abstract] [Full Text]  
• Flossmann, O, Bacon, P, de Groot, K, Jayne, D, Rasmussen, N, Seo, P, Westman, K, Luqmani, R (2008). Development of comprehensive disease assessment in systemic vasculitis. Postgrad. Med. J. 84: 143-152 [Abstract] [Full Text]  
• Tsiodras, S., Samonis, G., Boumpas, D. T., Kontoyiannis, D. P. (2008). Fungal Infections Complicating Tumor Necrosis Factor {alpha} Blockade Therapy. Mayo Clin Proc. 83: 181-194 [Abstract] [Full Text]  
• Aletaha, D, Strand, V, Smolen, J S, Ward, M M (2008). Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 67: 238-243 [Abstract] [Full Text]  
• Takeuchi, T, Tatsuki, Y, Nogami, Y, Ishiguro, N, Tanaka, Y, Yamanaka, H, Kamatani, N, Harigai, M, Ryu, J, Inoue, K, Kondo, H, Inokuma, S, Ochi, T, Koike, T (2008). Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189-194 [Abstract] [Full Text]  
• van der Heijde, D, Burmester, G, Melo-Gomes, J, Codreanu, C, Mola, E M., Pedersen, R, Freundlich, B, Chang, D J, for the Etanercept Study 400 Investigators, (2008). The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann Rheum Dis 67: 182-188 [Abstract] [Full Text]  
• Phelan, J. D., Orekov, T., Finkelman, F. D. (2008). Cutting Edge: Mechanism of Enhancement of In Vivo Cytokine Effects by Anti-Cytokine Monoclonal Antibodies. J. Immunol. 180: 44-48 [Abstract] [Full Text]  
• Soderlin, M K, Geborek, P (2008). Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 67: 37-42 [Abstract] [Full Text]  
• Kievit, W, Fransen, J, Oerlemans, A J M, Kuper, H H, van der Laar, M A F J, de Rooij, D J R A M, De Gendt, C M A, Ronday, K H, Jansen, T L, van Oijen, P C M, Brus, H L M, Adang, E M, van Riel, P L C M (2007). The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 66: 1473-1478 [Abstract] [Full Text]  
• Augustsson, J., Eksborg, S., Ernestam, S., Gullstrom, E., van Vollenhoven, R. (2007). Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 66: 1462-1466 [Abstract] [Full Text]  
• Verstappen, S M M, Jacobs, J W G, van der Veen, M J, Heurkens, A H M, Schenk, Y, ter Borg, E J, Blaauw, A A M, Bijlsma, J W J, on the behalf of the Utrecht Rheumatoid Arthritis, (2007). Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66: 1443-1449 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]  
• Vasilopoulos, Y, Gkretsi, V, Armaka, M, Aidinis, V, Kollias, G (2007). Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis. Ann Rheum Dis 66: iii23-iii28 [Abstract] [Full Text]